Immunotoxic Side-Effects of Drug Therapy

Mitchell, JA, Gillam, Emj, Stanley, LA and Sim, E (1990) Immunotoxic Side-Effects of Drug Therapy. Drug Safety, 5 3: 168-178. doi:10.2165/00002018-199005030-00002

Author Mitchell, JA
Gillam, Emj
Stanley, LA
Sim, E
Title Immunotoxic Side-Effects of Drug Therapy
Journal name Drug Safety   Check publisher's open access policy
ISSN 1179-1942
Publication date 1990-01-01
Year available 1990
Sub-type Critical review of research, literature review, critical commentary
DOI 10.2165/00002018-199005030-00002
Open Access Status
Volume 5
Issue 3
Start page 168
End page 178
Total pages 11
Place of publication AUCKLAND
Language eng
Subject 2736 Pharmacology (medical)
3004 Pharmacology
3005 Toxicology
2307 Health, Toxicology and Mutagenesis
2739 Public Health, Environmental and Occupational Health
Abstract Adverse reactions to drugs in which an immune mechanism is responsible for toxicity have been described as idiosyncratic. Understanding these toxic effects is important to enable the identification of patients at risk. The specific toxic side effects considered are heparin-induced thrombocytopenia, penicillin-induced haemolytic anaemia, hepatitis as a result of halothane and tienilic acid therapy, quinine- and quinidine-dependent thrombocytopenia, methyldopa-induced haemolytic anaemia and immune-complex disease following administration of hydralazine, procainamide and penicillamine. The molecular mechanisms of immunotoxicity are presented where such information is available, although more than one effect may contribute to the observed pattern of toxicity. The initial events leading to antibody production in certain individuals in response to drug therapy are not understood and, in many of the examples described, antibody production occurs in some patients who do not subsequently experience clinical problems. Clinically serious adverse effects involving immune reactions are infrequent, and a range of genetic and environmental circumstances need to be present simultaneously in an individual before toxicity develops. The ability to metabolise a particular drug has been shown to be one major predisposing factor in toxicity; the immunocompetence of the patient is likely to be another. Both of these considerations are subject to genetic and environmental controls, including infection and disease.
Keyword Public, Environmental & Occupational Health
Pharmacology & Pharmacy
Public, Environmental & Occupational Health
Pharmacology & Pharmacy
Q-Index Code C1
Q-Index Status Provisional Code
Institutional Status Unknown

Document type: Journal Article
Sub-type: Critical review of research, literature review, critical commentary
Collections: ResearcherID Downloads - Archived
Scopus Import - Archived
Version Filter Type
Citation counts: TR Web of Science Citation Count  Cited 9 times in Thomson Reuters Web of Science Article | Citations
Scopus Citation Count Cited 19 times in Scopus Article | Citations
Google Scholar Search Google Scholar
Created: Thu, 25 Feb 2016, 18:17:08 EST by System User